First positive results from TEDOPaM Ph 2 trial announced in advanced pancreatic cancer
Silvia Comis, MD, Chief Clinical and Medical Research Officer OSE Immunotherapeutics, commented: “We are pleased to share the latest clinical updates on our cancer vaccine Tedopi® at the ASCO Annual Meeting. Tedopi® combines 10 neo-epitopes derived from five tumor antigens, selected for their presence in a range of tumors, offering a multi-target “pipeline in a product” approach for HLA-A2 positive patients to address unmet needs in oncology. The positive results for Tedopi® in pancreatic cancer are promising for this devastating disease with a poor prognosis. We extend our gratitude to the GERCOR Oncology Group and the PRODIGE Intergroup, sponsors of the TEDOPaM study, for presenting these encouraging results at ASCO. In lung cancer, patient recruitment is progressing per plan in the Artemia Phase 3 registration study, a key milestone bringing us one step closer to the registration of Tedopi® for NSCLC. As previously communicated, the readouts of the combination Phase 2 trials, CombiTED for NSCLC and TEDOVA for ovarian cancer, are expected in 2026.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib